Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Int J Hematol
; 115(3): 350-362, 2022 Mar.
Article
in En
| MEDLINE
| ID: mdl-35072907
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oligopeptides
/
Psychomotor Performance
/
Frailty
/
Multiple Myeloma
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Int J Hematol
Journal subject:
HEMATOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Japón